Last reviewed · How we verify
Chemotherapy by Investigator's choice — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Chemotherapy by Investigator's choice (Chemotherapy by Investigator's choice) — AIO-Studien-gGmbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Chemotherapy by Investigator's choice TARGET | Chemotherapy by Investigator's choice | AIO-Studien-gGmbH | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Chemotherapy by Investigator's choice CI watch — RSS
- Chemotherapy by Investigator's choice CI watch — Atom
- Chemotherapy by Investigator's choice CI watch — JSON
- Chemotherapy by Investigator's choice alone — RSS
Cite this brief
Drug Landscape (2026). Chemotherapy by Investigator's choice — Competitive Intelligence Brief. https://druglandscape.com/ci/chemotherapy-by-investigator-s-choice. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab